Globally, the area of angiogenesis is dominated by investigations on anti-angiogenic agents and processes, due to its role in metastatic cancer treatment. Although, the area of ischemic tissue reperfusion is having much bigger demand and foot-mark. Following clinical failure of VEGF (Vascular endothelial growth factor) as a potential agent for induction of a controlled angiogenic response in ischemic tissues and organs, the progress is reasonably quiet as for new low molecular weight (LMW) angiogen molecules and their clinical applications are concerned.
Introduction
Controlled reperfusion of ischemic tissues is an active area of investigation both as an alternate approach of therapy and as the fundamental platform of in-situ cellular expansion in healing of wounds and restoration of blood supply in ischemic tissues. VEGF is the lead mitogen for endothelial cells. In human subjects, VEGF family consist of five different isoforms -VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF (placental growth factor) 1 . It plays a central role in the initiation of angiogenesis: regeneration and growth of new blood vessels at the capillary level. In vascular exchange beds, angiogenesis, which is an extremely conserved process across species, forms network of the supply lines for healthy cells by providing them required nutrients and gas, signaling molecules and by removal of carbon dioxide and other metabolic end products [1] [2] [3] [4] [5] [6] . As mentioned, angiogenesis is a highly conserved natural process and endogenously controlled by the body's own regulatory system. This system is considerably complex and precise, which involve both endogenous inhibitors and activators 6 . Degree of angiogenesis supports natural growth phase in the early part of life. However, with aging "normal angiogenic process" proves slow and inadequate for required growth at any given instance and in situations of very high demand for tissue repair and significant tissue regeneration. In-vivo angiogenesis is promoted through the production of VEGF by endothelial cells in the domains of relative ischaemia followed by its binding to the dedicated receptor VEGFR in the immediate vicinity. In addition, the VEGFR family consists of two non-protein kinases (neuropilin-1 and 2) and three receptor tyrosine kinases (VEGFR-1, VEGFR-2 and VEGFR-3) 1,4-6 . VEGFR-1 binds to VEGF-A, VEGF-B and PlGF; VEGFR-2 binds to VEGF-A, VEGF-C and VEGF-D; VEGFR-3 binds to VEGF-C and VEGF-D. VEGFR-1 and VEGFR-2 receptors are mainly found on the blood vascular endothelium and responsible for angiogenesis. However, VEGFR-3 receptors are mainly found on the lymphatic endothelium and responsible for lymphangiogenesis [2] [3] [4] . Moreover, in situations of relative ischaemia, depending on the degree, ischaemic zone endothelial cells elaborate excess titres of VEGF as a means of controlled ischaemia reperfusion 7, 8 .
Since, tumor angiogenesis or uncontrolled non-hierarchical angiogenesis play central role in proliferation of cancerous cells, the area of angiogenesis is mainly governed by studies on the inhibition of the process [9] [10] [11] [12] [13] [14] . In addition, the absence of a good candidate molecule as an effective mediator of induced angiogenic process the field of induced controlled augmented angiogenesis is substantially on a low key in the current global research trend.
Following clinical limitation of use of VEGF as a therapeutic agent, the area of controlled angiogenesis is evolving rather slowly, because of the absence of a non-toxic low-molecularweight angiogen molecule compared to rapid progresses made in the other half of angiogenesis research i.e. suppression of it 15 .
In this study, the potential of basic amino acid Lysine as a LMW-angiogen has been examined with the help of histopathological and CAM (Chorio-Allantoic-Membrane) experiments. 
Materials and Methods

Histopathological assay
Histopathological assay involved a surface wound treatment with bare 24-hourly topical application of hydrogel based Lysine HCl formulation (250 mg/g) to observe inducible angiogenesis in wound bed, if any. Human study was undertaken under all prescribed rules governing clinical evaluation studies, both at the controller general of drugs as well as the local institutional ethical committee levels. In addition, informed and explained patient consent was part of this clinical study. Following topical application for 5 days under moistened wound conditions, routine histopathology studies were carried out with tissue samples obtained from the peripheral margin of wound beds through punch biopsy.
CAM experiment
Chorio-Allantoic-Membrane (CAM) model was utilized to have confirmatory visual evidence of inducible angiogenesis as described earlier 14, [16] [17] [18] . Briefly, CAM of 9-days-old chicken embryos had been used in two groups: experimental group versus a control group, each group contains 5 embryos. Control CAMs were installed with aqueous vehicle (2 ml of water) only, whereas experimental group were supplemented with 2 ml of an aqueous solution of Lysine HCl (Ajinomoto Co., Japan). Both the sets of embryos were photographed after the 5 days incubation at 37 °C (to visualize the sprouting vessels).
In-silico docking analysis
The present section is mainly focused to the in-silico study of binding affinity of VEGF-A to This complex is then presented for binding with VEGF-A (1VPF).
ii) Lysine is first coupled to VEGF-A (1VPF) to generate the complex-VEGF-A-Lysine.
This complex peptide is then presented for binding studies with VEGF-A receptor (4KZN).
In protocol (i) above, VEGF-A receptor structure was scanned for distribution of surface negative charges along the entire length of the peptide. This was done in anticipation of a possible electrostatic interaction between added Lysine and the receptor peptide (Fig. 2a) .
Similarly, in pre-binding added lysine complexing protocol (ii) described above, VEGF-A molecule was screened for negative charge distribution along the entire length of the peptide molecule (Fig. 2d) . 
Results and Discussions
Histopathological assay
Lysine induced remarkably enhanced angiogenic response in the surface tissue repair of extensive bedsore was observed within approx. two weeks' time (Fig.3a) . Low and high power field optical microscopic representations of the tissue obtained from the margin of the wound bed through punch biopsy showed hierarchical angiogenic response in the wound bed (Fig. 3b, c) .
This clinical evidence of topical Lysine HCl gel mediated induction of an extensive angiogenic response in a profusely ischaemic wound bed possibly conforms to the hypothesis of the enhanced angiogenic response capability of the natural amino acid Lysine in ischemic tissues. 
CAM experiment
The ability of the amino acid as a potent angiogen was evaluated in in-vitro angiogenesis model.
Chicken embryo CAMs were supplemented with Lysine HCl in aqueous form (250 mg/ml). A 1 0
representative photograph showed sharp quantitative contrast in the angiogenic response in chicken embryo CAMs with and without Lysine in terms of growth of new capillaries (Fig. 4a,   b) . Substantive difference between the natural and lysine induced angiogenic response is obvious through the figures. 
In-silico docking analysis
Z-DOCK result for 4KZN (VEGF-A receptor) and Lysine (as a ligand) shows a specific location on VEGF-A receptor as the most probable binding site for added Lysine (Fig. 2b, c) .
Interestingly, although negative charge distribution among the entire body of the peptide was uniform (Fig. 2a) , added external lysine binding had a preferential binding site (Fig. 2b, c) .
Again, as observed in VEGF-A receptor-Lysine complexing study, VEGF-A showed a very dedicated binding site for the added single Lysine moiety, although unlike in VEGF-A receptor, VEGF-A showed few additional distributed comparatively insignificant locations of added Lysine binding sites also (Fig. 2e, f) . It is worth noting that the preferential and other lysine binding sites' distribution in the peptide are all being on either ends or on the tip of projected part of the peptide. Added Lysine (1:1) with VEGF-A and VEGF-A receptor gives more stable complex of the peptide-and-receptor (Fig. 5) , thereby inducing enhanced angiogenic response as seen clinically and experimentally (Fig. 3, 4) , where added lysine molecule with its functional groups -NH 2 (2) and -COOH (1) possibly helps in stabilizing "a probable loose-fit" between the ligand and the receptor.
Step 
Conclusions
Angiogenesis is a widely conserved process across species which forms the foundations for 
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